Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium–glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study

• Published in: Diabetes research and clinical practice 2021-10, Vol.180, p.109037-109037, Article 109037
• Main Authors: Son, Cheol, Makino, Hisashi, Kasahara, Masato, Tanaka, Tomohiro, Nishimura, Kunihiro, Taneda, S., Nishimura, Takeshi, Kasama, Shu, Ogawa, Yoshihiro, Miyamoto, Yoshihiro, Hosoda, Kiminori
• Format: Article
• Language: English
• Subjects: Body weight loss; Canagliflozin - therapeutic use; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - therapeutic use; Glucose - therapeutic use; Humans; Hypertension; Hypoglycemic Agents - therapeutic use; Japan - epidemiology; Lipid metabolism; Metabolic syndrome; Prospective Studies; Risk Factors; Sodium - therapeutic use; Thiazolidines
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2021.109037

•This study examined the effects of SGLT2 inhibitors and DPP-4 inhibitors on patients with early T2DM.•SGLT2 inhibitors are more beneficial to control metabolic risks than DPP-4 inhibitors in T2DM.•SGLT2 inhibitors are more effective for body weight reduction than DPP-4 inhibitors. The aim of this study was to compare the effectiveness of teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and canagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, at reducing a composite outcome of three metabolic risk factors (obesity, hypertension, and dyslipidemia) in Japanese patients with type 2 diabetes mellitus (T2DM) and metabolic risks. In this prospective, multicenter, open-label, randomized, parallel-group comparison study, 162 patients with T2DM and one or more metabolic risk factors were randomized into a teneligliptin or canagliflozin group and treated for 24 weeks. The primary endpoint was the composite percentage of subjects who experienced an improvement in at least one metabolic risk after 24 weeks of treatment. The primary endpoint was achieved significantly by more patients in the canagliflozin group than in the teneligliptin group (62.2% vs. 31.3%, p = 0.0004). A ≥ 3% body weight loss was also achieved by significantly more participants in the canagliflozin group than in the teneligliptin group (55.9% vs. 10.5%, p